Stockscreener 앱 받기
0.6717
3.34%
0.0249
전일 마감가:
$0.6468
열려 있는:
$0.6404
하루 거래량:
232.92K
Relative Volume:
0.15
시가총액:
$108.49M
수익:
-
순이익/손실:
$-274.18M
주가수익비율:
-0.265
EPS:
-2.5346
순현금흐름:
$-198.33M
1주 성능:
-0.21%
1개월 성능:
-40.85%
6개월 성능:
-95.24%
1년 성능:
-93.43%
1일 변동 폭
$0.632
$0.6775
1주일 범위
$0.627
$0.6913
52주 변동 폭
$0.6211
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
490 ARSENAL WAY, SUITE 200, WATERTOWN
NMRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
0.6722 | 108.49M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.74 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.27 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
603.29 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.93 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
231.54 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-03-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-10-10 | 개시 | BofA Securities | Buy |
| 2023-10-10 | 개시 | Guggenheim | Buy |
| 2023-10-10 | 개시 | JP Morgan | Overweight |
| 2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-10 | 개시 | Stifel | Buy |
| 2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Consensus PT from Analysts - MarketBeat
Alliancebernstein L.P. Sells 22,930 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Vanguard Group Inc. Purchases 195,142 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics' (NMRA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of “Hold” by Analysts - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc.: Strategic Advancements and Optimism Drive Buy Rating - TipRanks
Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Neumora Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion. - TradingView
Neumora Therapeutics, Inc. (NASDAQ: NMRA) Investor Alert: Deadline in Lawsuit on April 7, 2025 - openPR.com
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire
Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky about Pending Class ActionNMRA - ACCESS Newswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your RightsNMRA - PR Newswire
NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, - GlobeNewswire
NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. - Bluefield Daily Telegraph
NMRA IMPORTANT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Fir - TradingView
NMRA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of - GlobeNewswire
Faruqi & Faruqi Reminds Neumora Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - Morningstar
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
NMRA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit - The Malaysian Reserve
NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm - PR Newswire
Shareholders That Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky About Pending Class ActionNMRA - ACCESS Newswire
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora ... - Bluefield Daily Telegraph
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc.(NMRA) - GlobeNewswire
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Neumora Therapeutics, Inc. to Contact the Firm Today! - markets.businessinsider.com
Neumora Therapeutics' (NMRA) "Underperform" Rating Reaffirmed at Bank of America - MarketBeat
Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of - GuruFocus
Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - MarketScreener
Neumora Therapeutics (NASDAQ:NMRA) Earns “Underperform” Rating from Bank of America - Defense World
Shareholders that Lost Money on Neumora Therapeutics, Inc. (NMRA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire
NMRA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Fir - TradingView
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Neumora Therapeutics, Inc. to Contact the Firm Today! - markets.businessinsider.com
Neumora Therapeutics stock hits 52-week low at $0.88 - Investing.com
Shareholders of Neumora Therapeutics, Inc. Should Contact The Gross Law Firm Before April 7, 2025 to Discuss Your RightsNMRA - Morningstar
NMRA Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
NMRA Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Filing Deadline in Class Action Lawsuit - GlobeNewswire Inc.
2025-04-02 | Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky About Pending Class ActionNMRA | NDAQ:NMRA | Press Release - Stockhouse
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - Morningstar
NMRA Investors Have Final Opportunity to Lead Neumora Therapeuti - GuruFocus
NMRA Investors Have Final Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Neumora Therapeutics, Inc. Faces Setbacks with Delayed MDD Program and Discontinued Bipolar Depression Study - TipRanks
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - StreetInsider
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a - Bluefield Daily Telegraph
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Neumora Therapeutics Inc 주식 (NMRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
| Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
| Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
| Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
| Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
0.77%
0.11%
자본화:
|
볼륨(24시간):